Ocular Surface Diseases and Beyond
Oyster Point Pharma is committed to the discovery and development of first-in-class therapies to treat diseases of the ocular surface.
Leveraging our nicotinic acetylcholine receptor (nAChR) domain expertise, we are focused on the development of OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease, as well as a number of potential indications and uses associated with and beyond dry eye disease. These include neurotrophic keratopathy, dry eye associated with contact lens intolerance and ocular surface preparation for refractive surgeries.
OC-01 (varenicline) nasal spray is also an integral part of our proprietary, investigational Enriched Tear Film (ETF™) Gene Therapy in development for the treatment of select ocular surface diseases. Oyster Point Pharma’s investigational ETF™ Gene Therapy has been shown in preclinical models to deliver target genes to cells using adeno-associated virus (AAV) vectors, nonreplicating DNA delivery vehicles that are currently not known to cause disease. In preclinical models, it has been shown that the protein-producing machinery in the lacrimal gland can be harnessed to secrete selected proteins in the body’s own natural tear film to potentially treat diseases of the ocular surface. We believe that this approach has the potential to change the way that chronic diseases of the ocular surface are treated. Additionally, in preclinical models, it has been shown that OC-01 (varenicline) nasal spray may have the potential to modulate the amount of selected proteins, peptides, antibodies, hormones, enzymes or cytokines secreted from the lacrimal gland into the tear film and onto the ocular surface. We believe that targeting the parasympathetic nervous system through the use of cholinergic agonists, such as OC-01 (varenicline) nasal spray, administered locally in the nasal cavity has the potential to treat a wide range of diseases and disorders.